Interestingly, treatment of H82-KRASG12V cells with different combinations of inhibitors targeting MSK/RSK, CBP/p300, or ERG revealed that suppression of MYC by KRASG12V was well rescued by combined MSK/RSK and ERG inhibition that did not rescue suppressed expression of key NETFs, suggesting that oncogene-mediated ERK activation in SCLC modulates essential TFs through multiple regulatory mechanisms (Figure 6—figure supplement 3b). The gene discussed is RPS6KA2; the disease is small cell lung carcinoma.